These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1348351)

  • 1. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
    Gomez-Mancilla B; Boucher R; Bédard PJ
    Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ethosuximide on rest tremor in the MPTP monkey model.
    Gomez-Mancilla B; Latulippe JF; Boucher R; Bédard PJ
    Mov Disord; 1992; 7(2):137-41. PubMed ID: 1350061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
    Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
    Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
    Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
    Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
    Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M
    Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
    Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
    Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
    Gomez-Mancilla B; Boucher R; Bédard PJ
    Clin Neuropharmacol; 1991 Aug; 14(4):359-66. PubMed ID: 1913702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
    Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
    Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Yamaguchi M; Mizuta E; Kuno S
    Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
    Jenner P; Rose S; Nomoto M; Marsden CD
    Adv Neurol; 1987; 45():183-6. PubMed ID: 2881443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.